Doraid Alrifai
- Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
2020/12/01 by Priyanka Patel, on behalf of AstraZeneca UK Limited, Doraid Alrifai +3 · 11 citations
Medicine · #Cancer Immunotherapy and Biomarkers #Lung Cancer Treatments and Mutations #Lung Cancer Diagnosis and Treatment